Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.68 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21118406 | 0.98 | NOD1 (0.66) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL15975369 | 0.98 | NOD1 (0.66) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL17776319 | 0.98 | NOD1 (0.65) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL23677033 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL13902885 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL15975804 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL24178352 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL18116867 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL12673956 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 | |
| SCHEMBL12287733 | 0.95 | NOD1 (0.62) | NOD1SLC6A5KMT2AGNPATFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | NOD1 800/4885SLC6A5 2974/4885KMT2A 4174/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | NOD1 800/4885SLC6A5 2974/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.